We are now working more collaboratively than ever with our external stakeholders, as we know that we can’t achieve our goals alone.
Medical Research Council UK alliance
In December 2011 AstraZeneca and the Medical Research Alliance (MRC) created an alliance in which 22 previously studied AstraZeneca compounds were made available to academic researchers. Since then, the MRC and AstraZeneca have announced £7 million funding for 15 research projects involving those compounds.
This was recognised and rewarded at the SCRIP Awards in December 2012, receiving the ‘Best Partnership Alliance’.
Manchester Cancer Research Centre (MCRC) Tissue Bank
AstraZeneca and Manchester Cancer Research Centre have worked together to establish the MCRC tissue bank.
Five Manchester hospitals now have a standardised approach to collection of tissue, blood and urine, linked with clinical outcome data.
Over 1,600 samples have been collected in broad range of tumours, giving opportunities for academia and commercial researchers access to valuable clinical samples.
Cancer Research UK Stratified Medicines
Working together with AstraZeneca, Pfizer and the Government, CRUK aims to establish a national service making standardised, high quality, cost-effective genetic testing of tumours available for people with cancer. So, as and when targeted treatments become available, doctors will have access to the tests needed to help them decide the most suitable drugs for each individual patient.
At the same time, by routinely collecting samples from consenting patients, CRUK will build a national database of tumour genetic information, treatments and outcomes that will enable us all to design more effective cancer treatments in future.
Manchester Collaborative Centre for Inflammation
AstraZeneca is partnering with the University of Manchester and GSK to create the Manchester Collaborative Centre for Inflammation, a unique joint venture designed to establish a world-leading translational research centre in the UK for inflammatory diseases which affect the joints, lungs, skin and many other organs in the body.
To succeed now and in the future, we know that we will have to continue investing in our own R&D capability and actively seek strategic partnerships outside our own laboratories.
These partnerships are part of our commitment to seeking out the best innovative science, inside and outside our business. We’ve forged some key partnerships in the UK, plus we’re backing the work of external organisations by supporting research into new medicines and their use in patient care.
Globally, recent deals have involved not only in-licensing and acquisitions, but also risk sharing, spin-outs, divestments, out-licensing, fostering and early stage research collaborations. Find out more about these activities at our global website.
Our primary focus is on our core disease areas: cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.
But we also have a dedicated team looking outside for the next generation of innovations, reviewing our own pipeline for other disease applications, and joining the fight against developing world diseases such as TB and malaria.
2558100 May 2013